265 related articles for article (PubMed ID: 33423516)
1. Serum Neurofilament to Magnetic Resonance Imaging Lesion Area Ratio Differentiates Spinal Cord Infarction From Acute Myelitis.
Sechi E; Mariotto S; McKeon A; Krecke KN; Pittock SJ; Ferrari S; Monaco S; Flanagan EP; Zanzoni S; Rabinstein AA; Wingerchuk DM; Nasr DM; Zalewski NL
Stroke; 2021 Jan; 52(2):645-654. PubMed ID: 33423516
[TBL] [Abstract][Full Text] [Related]
2. Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody.
Dubey D; Pittock SJ; Krecke KN; Morris PP; Sechi E; Zalewski NL; Weinshenker BG; Shosha E; Lucchinetti CF; Fryer JP; Lopez-Chiriboga AS; Chen JC; Jitprapaikulsan J; McKeon A; Gadoth A; Keegan BM; Tillema JM; Naddaf E; Patterson MC; Messacar K; Tyler KL; Flanagan EP
JAMA Neurol; 2019 Mar; 76(3):301-309. PubMed ID: 30575890
[TBL] [Abstract][Full Text] [Related]
3. The frequency of longitudinally extensive transverse myelitis in MS: A population-based study.
Asnafi S; Morris PP; Sechi E; Pittock SJ; Weinshenker BG; Palace J; Messina S; Flanagan EP
Mult Scler Relat Disord; 2020 Jan; 37():101487. PubMed ID: 31707235
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Clinical Outcomes of Transverse Myelitis Among Adults With Myelin Oligodendrocyte Glycoprotein Antibody vs Aquaporin-4 Antibody Disease.
Mariano R; Messina S; Kumar K; Kuker W; Leite MI; Palace J
JAMA Netw Open; 2019 Oct; 2(10):e1912732. PubMed ID: 31596489
[TBL] [Abstract][Full Text] [Related]
5. Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity.
Chien C; Scheel M; Schmitz-Hübsch T; Borisow N; Ruprecht K; Bellmann-Strobl J; Paul F; Brandt AU
Mult Scler; 2019 Dec; 25(14):1926-1936. PubMed ID: 30475082
[TBL] [Abstract][Full Text] [Related]
6. Clinical and Radiologic Features Among Children With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Myelitis.
Ren C; Zhang W; Zhou A; Zhou J; Cheng H; Tang X; Fang F; Ren X
Pediatr Neurol; 2023 Jun; 143():96-99. PubMed ID: 37060644
[TBL] [Abstract][Full Text] [Related]
7. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
[TBL] [Abstract][Full Text] [Related]
8. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
[TBL] [Abstract][Full Text] [Related]
9. Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies.
Sechi E; Krecke KN; Pittock SJ; Dubey D; Lopez-Chiriboga AS; Kunchok A; Weinshenker BG; Zalewski NL; Flanagan EP
Mult Scler; 2021 Feb; 27(2):303-308. PubMed ID: 32103708
[TBL] [Abstract][Full Text] [Related]
10. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.
Mader S; Gredler V; Schanda K; Rostasy K; Dujmovic I; Pfaller K; Lutterotti A; Jarius S; Di Pauli F; Kuenz B; Ehling R; Hegen H; Deisenhammer F; Aboul-Enein F; Storch MK; Koson P; Drulovic J; Kristoferitsch W; Berger T; Reindl M
J Neuroinflammation; 2011 Dec; 8():184. PubMed ID: 22204662
[TBL] [Abstract][Full Text] [Related]
11. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance imaging in enterovirus-71, myelin oligodendrocyte glycoprotein antibody, aquaporin-4 antibody, and multiple sclerosis-associated myelitis in children.
Tantsis EM; Prelog K; Alper G; Benson L; Gorman M; Lim M; Mohammad SS; Ramanathan S; Brilot F; Dale RC;
Dev Med Child Neurol; 2019 Sep; 61(9):1108-1116. PubMed ID: 30537075
[TBL] [Abstract][Full Text] [Related]
13. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.
van Pelt ED; Wong YY; Ketelslegers IA; Hamann D; Hintzen RQ
Eur J Neurol; 2016 Mar; 23(3):580-7. PubMed ID: 26593750
[TBL] [Abstract][Full Text] [Related]
14. Different magnetic resonance imaging features between MOG antibody- and AQP4 antibody-mediated disease: A Chinese cohort study.
Chen C; Liu C; Fang L; Zou Y; Ruan H; Wang Y; Cui C; Sun X; Peng L; Qiu W
J Neurol Sci; 2019 Oct; 405():116430. PubMed ID: 31465985
[TBL] [Abstract][Full Text] [Related]
15. MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation.
Loos J; Pfeuffer S; Pape K; Ruck T; Luessi F; Spreer A; Zipp F; Meuth SG; Bittner S
J Neurol; 2020 Jun; 267(6):1632-1642. PubMed ID: 32055995
[TBL] [Abstract][Full Text] [Related]
16. Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology.
Sechi E; Shosha E; Williams JP; Pittock SJ; Weinshenker BG; Keegan BM; Zalewski NL; Lopez-Chiriboga AS; Jitprapaikulsan J; Flanagan EP
Neurology; 2019 Jul; 93(4):e414-e420. PubMed ID: 31235660
[TBL] [Abstract][Full Text] [Related]
17. Marked central canal T2-hyperintensity in MOGAD myelitis and comparison to NMOSD and MS.
Webb LM; Cacciaguerra L; Krecke KN; Chen JJ; Sechi E; Redenbaugh V; Dubey D; Pittock SJ; Flanagan EP
J Neurol Sci; 2023 Jul; 450():120687. PubMed ID: 37201267
[TBL] [Abstract][Full Text] [Related]
18. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
[TBL] [Abstract][Full Text] [Related]
19. [Clinical characteristics of myelin oligodendrocyte glycoprotein antibody associated myelitis].
Zhangbao BJZ; Zhou L; Wang L; Huang WJ; Zhao CB; Lu JH; Quan C
Zhonghua Yi Xue Za Zhi; 2020 Feb; 100(5):334-338. PubMed ID: 32074775
[No Abstract] [Full Text] [Related]
20. MOG-IgG myelitis coexisting with systemic lupus erythematosus in the post-partum setting.
Bilodeau PA; Kumar V; Rodriguez AE; Li CT; Sanchez-Alvarez C; Thanarajasingam U; Zalewski NL; Flanagan EP
Mult Scler; 2020 Jul; 26(8):997-1000. PubMed ID: 31621483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
